Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

Nabergoj, Sanja (avtor), Mlinarič-Raščan, Irena (avtor), Jakopin, Žiga (avtor)

In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side-effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has already been approved in Europe by the European Medicine Agency for treating patients with osteosarcoma in combination with chemotherapy after complete surgical removal of the primary tumor. This review is focused on NOD receptors as promising targets in cancer immunotherapy as well as summarizing current knowledge of the various NOD ligands exhibiting antitumor and even antimetastatic activity in vitro and in vivo.

• Jezik: Angleški jezik
• Ključne besede: adjuvants, cancer immunotherapy, immunotherapeutics, NOD1 agonists, NOD1 antagonists, NOD2 agonists, NOD2 antagonists
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2019
• Št. strani: Str. 1447-1484
• Številčenje: Vol. 39, iss. 5
• PID: 20.500.12556/RUL-125359
• UDK: 615.4:54
• ISSN pri članku: 1098-1128
• DOI: 10.1002/med.21557
• COBISS.SI-ID: 4641905
• Datum objave v RUL: 12.03.2021

Gradivo je del revije

• Naslov: Medicinal research reviews
• Skrajšan naslov: Med. res. rev.
• Založnik: Wiley
• ISSN: 1098-1128
• COBISS.SI-ID: 512824089

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 12.03.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: ligandi, imunoterapevtiki, NOD1 agonisti, NOD1 antagonisti, NOD2 agonisti, NOD2 antagonisti

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P1-0208
• Naslov: Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin